Who are Tezspire's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TEZSPIRE, Tezspire, tezepelumab (Arm1&Arm2), Experimental: Tezepelumab, Biological: Experimental: Tezepelumab, Tezspire.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg-157.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tezspire — Competitive Intelligence Brief

Tezspire (AMG 157) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thymic Stromal Lymphopoietin Blocker [EPC]. Area: Respiratory.

marketed Thymic Stromal Lymphopoietin Blocker [EPC] Thymic stromal lymphopoietin Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Tezspire (AMG 157) — AstraZeneca. Tezspire blocks the action of Thymic Stromal Lymphopoietin (TSLP), a protein that triggers inflammation in the airways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tezspire TARGET	AMG 157	AstraZeneca	marketed	Thymic Stromal Lymphopoietin Blocker [EPC]	Thymic stromal lymphopoietin	2021-01-01
TEZSPIRE	TEZEPELUMAB-EKKO	ASTRAZENECA AB	marketed	Thymic Stromal Lymphopoietin Blocker [EPC]	Thymic stromal lymphopoietin
Tezspire	Tezspire	Qilu Pharmaceutical Co., Ltd.	marketed		Thymic stromal lymphopoietin
tezepelumab (Arm1&Arm2)	tezepelumab (Arm1&Arm2)	Qilu Pharmaceutical Co., Ltd.	phase 3	Monoclonal antibody	Thymic stromal lymphopoietin (TSLP)
Experimental: Tezepelumab	Experimental: Tezepelumab	AstraZeneca	phase 3	Monoclonal antibody; TSLP inhibitor	TSLP (Thymic Stromal Lymphopoietin)
Biological: Experimental: Tezepelumab	Biological: Experimental: Tezepelumab	AstraZeneca	phase 3	TSLP antagonist monoclonal antibody	TSLP (Thymic Stromal Lymphopoietin)
Tezspire	TEZEPELUMAB	AstraZeneca / Amgen	marketed	Thymic Stromal Lymphopoietin Blocker [EPC]		2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thymic Stromal Lymphopoietin Blocker [EPC] class)

ASTRAZENECA AB · 1 drug in this class
AstraZeneca · 1 drug in this class
AstraZeneca / Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tezspire — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-157. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab